<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34881371</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-6065</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet regional health. Western Pacific</Title><ISOAbbreviation>Lancet Reg Health West Pac</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial.</ArticleTitle><Pagination><StartPage>100284</StartPage><MedlinePgn>100284</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100284</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanwpc.2021.100284</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">China's three inactivated enterovirus A71 (EV-A71) vaccines are the first and currently world's only EV-A71 vaccines approved by a national regulatory authority and used to prevent EV-A71 associated diseases. The three vaccines vary by vaccine strain, manufacturing cell substrate, and antigen dose, but no head-to-head comparisons of these vaccines have been done. We compared immunogenicity of the vaccines in children 6-35 months old.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited healthy children aged 6-35 months who lived in a study site county into a multicentre, open-label, non-inferiority, three-group, randomised controlled trial that was conducted in five counties in China. Enrolled children were randomly assigned (1:1:1) to receive two doses of one of the three EV-A71 vaccines. The primary outcome was the proportion of children with EV-A71 neutralizing antibody seroconversion 4 weeks after the second dose; a secondary outcome was adverse events in the 4 weeks after each dose. Analyses of immunogenicity included all children who completed the study (per-protocol analysis). Safety analysis included all children completed safety follow-up after at least one. We used a 10% margin to establish non-inferiority. This trial was registered on a World Health Organization platform: Chinese Clinical Trial Registry (ChiCTR1900026663).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">1631 children were assessed for eligibility between Nov 4 and Nov 20, 2019. Of 1500 (92%) enrolled children, 500 were assigned to vaccine group A, B, or C; 483 in group A,484 in group B, and 487 in group C completed the study. Before dose one, the seropositive rates in groups A, B, and C were 9.7%, 7.2%, and 7.0%. Four weeks after the second dose, seroconversion rates of groups A, B, and C were 98.8%, 99.4% and 99.8% - mutually non-inferior in all two-group comparisons. There were no serious adverse events in any group and no evidence of a difference among the three groups in the incidence of local adverse event or systemic adverse event. Fever was the most common adverse event. All children with reported adverse events recovered.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Non-inferior and high seroconversion rates and equivalent safety of three EV-A71 vaccines supports use any of these vaccines to prevent EV-A71-associated diseases. These results may be useful for regulators, vaccine policy makers, and immunization programmes in China and in countries where EV-A71 is endemic.</AbstractText><CopyrightInformation>© 2021 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yamin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Baoding prefectural Center for Disease Control and Prevention, Baoding, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Huakun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shenyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yunnan Provincial Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yunnan Provincial Center for Disease Control and Prevention, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Keli</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huaqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zundong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Zhijie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Zijian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health West Pac</MedlineTA><NlmUniqueID>101774968</NlmUniqueID><ISSNLinking>2666-6065</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">children aged 6-35 months</Keyword><Keyword MajorTopicYN="N">inactivated enterovirus-A71 vaccines</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>We declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34881371</ArticleId><ArticleId IdType="pmc">PMC8579145</ArticleId><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100284</ArticleId><ArticleId IdType="pii">S2666-6065(21)00193-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, PereraD Teo B, Wee TY, Yao SC, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health. 2006;6:180. doi: 10.1186/1471-2458-6-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-6-180</ArticleId><ArticleId IdType="pmc">PMC1543637</ArticleId><ArticleId IdType="pubmed">16827926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the outbreak study group. Clin Infect Dis. 2000;31:678–683. doi: 10.1086/314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46:621–627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71. Singapore. Emerg Infect Dis. 2003;9:78–85. doi: 10.3201/eid0901.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0901.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Tu P, Thao NTT, Perera D, Truong KH, Tien NTK, Thuong TC, How OM, Cardosa MJ, McMinn PC. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007;13:1733–1741. doi: 10.3201/eid1311.070632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1311.070632</ArticleId><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People's Republic of China. National surveillance of epidemic situation of notifiable communicable diseases in 2017 in China. Reviewed Jan 18 [accessed 2018 July 6]. http://www.nhfpc.gov.cn/jkj/s3578/201801/</Citation></Reference><Reference><Citation>National Medical Products Administration. http://app1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=25&amp;tableName=TABLE25&amp;title=%E5%9B%BD%E4%BA%A7%E8%8D%AF%E5%93%81&amp;bcId=152904713761213296322795806604.Downloaddate:2020-2-12.</Citation></Reference><Reference><Citation>National Institute for Food and Drug Control. Summary of the publicity of biological products batch issuance products. https://www.nifdc.org.cn/nifdc/fwzn/swzppqfxxpt/index.html. Download date:2020-2-12.</Citation></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, Shen X, Wang J. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668–9674. doi: 10.1016/j.vaccine.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper Gillian, Mao Qunying, Crawt Laura, Wang Yiping, Dougall Thomas, Rigsby Peter, et al. World Health Organization; Geneva: 2018. Report of the WHO collaborative study to establish the 1st WHO International Standard for anti-EV71 serum (Human) WHO/BS/2015.2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedcastle Alison, Mao Qunying, Hockley Jason, Pegg Elaine, EV71 Study Group, Gao Fan, et al. World Health Organization; Geneva: 2019. Report on the WHO collaborative study to establish the 1st International Standard for Enterovirus A71 inactivated vaccine. WHO/BS/2019.2362.</Citation></Reference><Reference><Citation>Chiu Mu-Lin, Luo Shu-Ting, Chen Ya-Yen, Chung Wan Yu, Duong Veasna, Dussart Philippe, et al. Establishment of Asia-Pacific Network for Enterovirus Surveillance. Vaccine. 2020;38:1–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31679864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Dong C, Li X, Gao Q, Guo Z, et al. Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV-A71 Vaccines in Mice. PLOS ONE. 2012;7(9):e46043. doi: 10.1371/journal.pone.0046043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046043</ArticleId><ArticleId IdType="pmc">PMC3460965</ArticleId><ArticleId IdType="pubmed">23029378</ArticleId></ArticleIdList></Reference><Reference><Citation>Qun-ying Mao, Yiping Wang, Lianlian Bian, Miao Xu, Zhenglun Liang. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD), Expert Review of Vaccines, 2016;15:5, 599-606. 10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25:19–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Li N, Yu X, Yao X, Li FX, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2011;157:37–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Maounying Gao Fan, Lianlian Bian, Bopei Cui, Ruixiao Du, Miao XU, et al. Assignment of international unit for national enterovirus 71 neutralizing antibody standard in China. Chin J Viral Dis. 2018;8(6):469–475.</Citation></Reference><Reference><Citation>WHO. Global manual on surveillance of adverse events following immunization. 2014. http://www.who.int/vaccine_safety/publications/aefi_surveillance/en/ (accessed Nov 18, 2020).</Citation></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71vaccine in healthy children. N Engl J Med. 2014;370:829–837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Jin P, Li JX, et al. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate end points. Expert Rev Vaccines. 2017;16(9):945–949.</Citation><ArticleIdList><ArticleId IdType="pubmed">28548626</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Yu FH, et al. Purification and characterization of enterovirus 71 viral particles produced from Vero Cells grown in a serum –free microcarrier bioreatctor system. PloS ONE. 2011;6(5):e20005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XX, Wei Peng, Ren JS, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nature Structural &amp; Molecular Biology. 2012;19:424–429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>jing Zhang. Trend of epidemics and variation of pathogen of hands, foot and mouth diseases in China: a dynamic series analysis,2008-2007. Chin J Epidemiol. 2019;40(2):147–154.</Citation><ArticleIdList><ArticleId IdType="pubmed">30744263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84(7):3339–3350. doi: 10.1128/JVI.01019-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17(6):371–379.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD). http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf (accessedNov11, 2019).</Citation></Reference><Reference><Citation>Liu P, Yuan Y, Cui B, Huo Y, Bian L, Chen L, Liu S, Wang C, Xu Y, Tedcastle A, et al. Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy. Viruses. 2021;13:720. doi: 10.3390/v13050720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050720</ArticleId><ArticleId IdType="pmc">PMC8143144</ArticleId><ArticleId IdType="pubmed">33919184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, et al. The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children. PLoS ONE. 2013;8(11):e79599. doi: 10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>